H. Samonigg

4.2k total citations
72 papers, 2.7k citations indexed

About

H. Samonigg is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, H. Samonigg has authored 72 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Oncology, 22 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in H. Samonigg's work include Breast Cancer Treatment Studies (17 papers), Cancer Treatment and Pharmacology (13 papers) and Estrogen and related hormone effects (9 papers). H. Samonigg is often cited by papers focused on Breast Cancer Treatment Studies (17 papers), Cancer Treatment and Pharmacology (13 papers) and Estrogen and related hormone effects (9 papers). H. Samonigg collaborates with scholars based in Austria, Germany and United States. H. Samonigg's co-authors include Armin Gerger, Michael Stotz, Joanna Szkandera, Tatjana Stojaković, Gudrun Absenger, Martin Pichler, Michael Gnant, R. Jakesz, Renate Schaberl-Moser and E. Kubista and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

H. Samonigg

70 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Samonigg Austria 26 1.8k 905 482 463 379 72 2.7k
P. Fargeot France 30 1.7k 1.0× 899 1.0× 575 1.2× 340 0.7× 355 0.9× 87 2.7k
Ishmael Jaiyesimi United States 21 1.3k 0.7× 537 0.6× 784 1.6× 387 0.8× 632 1.7× 119 3.1k
Carlo Tondini Italy 28 1.2k 0.7× 567 0.6× 476 1.0× 210 0.5× 363 1.0× 104 2.3k
S.C. Henzen‐Logmans Netherlands 29 1.2k 0.7× 811 0.9× 366 0.8× 347 0.7× 862 2.3× 60 2.7k
Giuseppe Colucci Italy 27 2.0k 1.1× 576 0.6× 1.1k 2.3× 362 0.8× 615 1.6× 123 3.7k
G. Bonadonna Italy 25 1.9k 1.1× 1.3k 1.5× 585 1.2× 407 0.9× 468 1.2× 72 3.3k
Barry C. Lembersky United States 31 2.5k 1.4× 1.1k 1.2× 764 1.6× 269 0.6× 276 0.7× 82 3.3k
P. Sevelda Austria 26 906 0.5× 482 0.5× 304 0.6× 231 0.5× 427 1.1× 137 2.7k
Alex McMillan United States 33 944 0.5× 716 0.8× 712 1.5× 322 0.7× 861 2.3× 57 3.5k
W. Lichtenegger Germany 35 1.8k 1.0× 1.1k 1.2× 548 1.1× 271 0.6× 1.0k 2.7× 243 4.6k

Countries citing papers authored by H. Samonigg

Since Specialization
Citations

This map shows the geographic impact of H. Samonigg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Samonigg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Samonigg more than expected).

Fields of papers citing papers by H. Samonigg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Samonigg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Samonigg. The network helps show where H. Samonigg may publish in the future.

Co-authorship network of co-authors of H. Samonigg

This figure shows the co-authorship network connecting the top 25 collaborators of H. Samonigg. A scholar is included among the top collaborators of H. Samonigg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Samonigg. H. Samonigg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Szkandera, Joanna, Sereina A. Herzog, Martin Pichler, et al.. (2015). LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy. The Pharmacogenomics Journal. 15(5). 391–396. 12 indexed citations
2.
Hofmann, G, Marija Balić, Nadia Dandachi, et al.. (2013). The predictive value of serum soluble E-cadherin levels in breast cancer patients undergoing preoperative systemic chemotherapy. Clinical Biochemistry. 46(15). 1585–1589. 17 indexed citations
3.
Szkandera, Joanna, Michael Stotz, Gudrun Absenger, et al.. (2013). Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients. British Journal of Cancer. 110(1). 183–188. 162 indexed citations
4.
Absenger, Gudrun, Léonor Benhaïm, Joanna Szkandera, et al.. (2013). The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy. The Pharmacogenomics Journal. 14(2). 130–134. 16 indexed citations
5.
Tse, Gary, Klara Belaj, Martin Pichler, et al.. (2012). Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. British Journal of Cancer. 107(8). 1244–1248. 38 indexed citations
6.
Bauernhofer, Thomas, Martin Pichler, Eva Wieckowski, et al.. (2011). Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck. British Journal of Cancer. 104(10). 1641–1648. 14 indexed citations
7.
Gerger, Armin, Rainer Hofmann‐Wellenhof, Uwe Langsenlehner, et al.. (2008). In vivo confocal laser scanning microscopy of melanocytic skin tumours: diagnostic applicability using unselected tumour images. British Journal of Dermatology. 158(2). 329–333. 59 indexed citations
8.
Asslaber, Martin, Peter M. Abuja, Johann Eder, et al.. (2007). The Genome Austria Tissue Bank (GATiB). Pathobiology. 74(4). 251–258. 22 indexed citations
9.
Schippinger, Walter, H. Samonigg, Renate Schaberl-Moser, et al.. (2007). A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. British Journal of Cancer. 97(8). 1021–1027. 82 indexed citations
10.
Horn, M., Armin Gerger, Sílvia Helena Koller, et al.. (2006). The use of confocal laser-scanning microscopy in microsurgery for invasive squamous cell carcinoma. British Journal of Dermatology. 156(1). 81–84. 33 indexed citations
11.
Bauernhofer, Thomas, F. Ploner, I. Kuss, et al.. (2003). Acute Pseudo-Obstruction of the Small Intestine Following High-Dose Chemotherapy and Stem Cell Support. Oncology Research and Treatment. 26(4). 344–346. 1 indexed citations
12.
Baider, Lea, Elisabeth Andritsch, Beatrice Uziely, et al.. (2003). Effects of age on coping and psychological distress in women diagnosed with breast cancer: review of literature and analysis of two different geographical settings. Critical Reviews in Oncology/Hematology. 46(1). 5–16. 57 indexed citations
13.
Wolf, Gerald, Reingard Aigner, Tobias Schwarz, Peter Krippl, & H. Samonigg. (2003). Diagnosis of a Contralateral Second Testicular Carcinoma by F18-FDG PET. Oncology Research and Treatment. 26(2). 155–157. 3 indexed citations
14.
Jakesz, R., H. Hausmaninger, & H. Samonigg. (2002). Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer. European Journal of Cancer. 38(3). 327–332. 11 indexed citations
15.
Birner, P., Georg Oberhuber, Josefine Stani, et al.. (2001). Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.. PubMed. 7(6). 1669–75. 159 indexed citations
16.
Bauernhofer, Thomas, Herbert Stöger, F. Ploner, et al.. (1999). Combined Treatment of Metastatic Osteosarcoma of the Spine. Oncology. 57(4). 265–268. 4 indexed citations
17.
Jakesz, R., H. Hausmaninger, K. Haider, et al.. (1999). Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node–Positive Breast Cancer. Journal of Clinical Oncology. 17(6). 1701–1701. 28 indexed citations
18.
Stöger, Herbert, H. Samonigg, Michael Krainer, et al.. (1998). Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. European Journal of Cancer. 34(4). 482–488. 12 indexed citations
19.
Hausmaninger, H., Heinz Ludwig, Michael Fridrik, et al.. (1995). 5-Fluorouracil and Folinic Acid with or without Alpha-2c Interferon in the Treatment of Metastatic Colorectal Cancer: Preliminary Results of a Multicenter Prospective Randomized Phase-Ill Trial. Oncology Research and Treatment. 18(2). 131–135. 1 indexed citations
20.
Hausmaninger, H., M. Lehnert, Guenther G. Steger, et al.. (1995). Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer. European Journal of Cancer. 31(13-14). 2169–2173. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by P. Fargeot Breakdown of academic impact, for papers by Ishmael Jaiyesimi Breakdown of academic impact, for papers by Carlo Tondini Breakdown of academic impact, for papers by S.C. Henzen‐Logmans Breakdown of academic impact, for papers by Giuseppe Colucci Breakdown of academic impact, for papers by G. Bonadonna Breakdown of academic impact, for papers by Barry C. Lembersky Breakdown of academic impact, for papers by P. Sevelda Breakdown of academic impact, for papers by Alex McMillan Breakdown of academic impact, for papers by W. Lichtenegger
Rankless by CCL
2026